Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00339287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Amendment history

The 50 most recent of 309 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor

    Re-verified, no change to tracked fields

  2. Minor

    Re-verified, no change to tracked fields

  3. Minor

    Eligibility criteria expanded, about 7 words

    Study description expanded, about 3 words; Publications: details revised at 2 of 2 entries

    Show what changed: Eligibility criteria
    * INCLUSION \& EXCLUSION CRITERIA: Volunteers will be selected from a hea [...] RML. The specific criteria for eligibility are as follows: * Subjects must fit the definition of "healthy adults" as asse [...] to have blood and/or tissue samples stored for future use. * Inasmuch as all subjects are RML employees, they will be 18 years of age or older. * Children are excluded. * Pregnant women will be identified by verbal history and are not eligible to donate blood for this protocol. * The study population will be all-inclusive except in certain [...] ide influences such as recent bacterial or viral infection. * I [...]
    Show what changed: Study description
    [...] isorders. Therefore, projects will address 3 specific aims: 1. Identify and characterize specific mechanisms used by pathog [...] ert normal phagocyte responses and therefore cause disease. 2. Investigate phagocyte response mechanisms to specific pathogenic microorganisms. 3. Identify specific bacterial structures and/or (gene) product [...]
  4. Minor

    47 amendments

    47 re-verifications since 2024-08-07, no change to tracked fields

    v260-v306

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Human phagocytic cells such as polymorphonuclear leukocytes (PMNs) are readily mobilized to sites of infection and ingest microorganisms by a process known as phagocytosis. The combined effects of reactive oxygen species (ROS) and proteolytic peptides and enzymes released into forming bacterial phagosomes kill most ingested bacteria. However, many human bacterial pathogens have devised means to subvert normal phagocyte responses and the innate immune response and cause severe disease. The overall objective of this study is to elucidate specific features of pathogen-phagocyte interactions that underlie evasion of the innate immune response or contribute to the pathophysiology of disease or inflammatory disorders. Therefore, specific projects will: 1. Identify and characterize specific mechanisms used by pathogenic microorganisms to evade or subvert normal phagocyte responses and therefore cause disease. 2. Investigate phagocyte response mechanisms to specific pathogenic microorganisms. 3. Identify specific bacterial structures and/or (gene) products that dictate differences in phagocyte responses among a range of pathogens so that generalized statements can be made about the pathophysiology of disease states. The studies will be performed using multiple techniques including state-of-the-art equipment for genomics and proteomics strategies to identify target bacterial genes/proteins of interest or those up-regulated in phagocytes. Phagocyte-pathogen interactions will be examined using fluorescence-based real-time assays and video microscopy, confocal and electron microscopy in combination with enzymatic assays for ROS production, routine biochemistry, immunology and cell biology. Implementing these studies will require isolation of phagocytic leukocytes from venous blood of healthy human volunteers. The study population will be all-inclusive except in certain instances where individuals possess genetic defects that impair phagocyte function (e.g., myeloperoxidase-deficiency) or have altered phagocyte function due to outside influences such as recent bacterial or viral infection. The proposed studies will likely provide new information pertinent to understanding host cell-pathogen interactions and the pathophysiology of inflammatory conditions....
Trial Details
NCT Number NCT00339287
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Host Defense Mechanisms
Enrollment 200 participants
Start Date
Updated on ClinicalTrials.gov